Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Endometrial Cancer

Trial Information

A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer [GOG0209]

This research study is for women who have been diagnosed with cancer of the endometrium (lining of the womb) that cannot be treated with surgery or radiation therapy. The purpose of this study is to find out whether treatment with the two-drug combination of carboplatin and paclitaxel is as good as the current standard three-drug combination of cisplatin, doxorubicin, and paclitaxel. Study participants will be randomly assigned (by chance) to receive either the 2-drug or the 3-drug combination.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are 18 years of age or older
-have been diagnosed with Stage 3 or 4 endometrial cancer
-meet additional criteria

You will not be eligible to participate if you
-currently have an additional type of cancer other than skin cancer
-have received prior cytotoxic chemotherapy, including chemotherapy used for radiation sensitization

Rudy Segna, MD
Mount Sinai Medical Center
One Gustave L. Levy Place

New York, NY 10029
Phone: 212-888-8439
Fax: (212) 319-1140
EMail: rudy.segna@mssm.edu

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.